Overview: Parvovirus B19 IgM TestIntroduction: The Parvovirus B19 IgM Test detects Parvovirus B19 IgM to diagnose recent infection, causing rash or joint pain. Aligned with 2023 IDSA guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected recent parvovirus B19 infection, particularly in pregnant women or immunocompromised individuals.
Other Names: Parvovirus IgM Assay, B19 Recent Infection Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Parvovirus B19 antibody testing began in the 1980s with viral discovery. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Parvovirus B19 IgM to diagnose recent infection, guides treatment, and evaluates patients with rash or joint pain.
Test Parameters: 1. Parvovirus B19 IgM Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of rash, joint pain, or parvovirus exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document rash, joint pain, or history of parvovirus exposure. Include current medications, especially in pregnancy or immunosuppression.
Consent: Written consent required, detailing the tests purpose, parvovirus infection implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect Parvovirus B19 IgM. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for recent infection diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other viruses may reduce specificity.
Clinical Significance: Positive IgM confirms recent infection, guiding monitoring or supportive care. Negative results may require PCR testing.
Specialist Consultation: Consult an infectious disease specialist or obstetrician for result interpretation and treatment planning.
Additional Supporting Tests: Parvovirus B19 PCR, IgG testing, or fetal ultrasound to confirm recent parvovirus infection.
Test Limitations: IgM may persist post-infection; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Parvovirus Guidelines, 2023; Clinical Infectious Diseases, Young NS, 2022.
